| 标题 |
First-in-class PD-1/IL-2 α-bias bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non–small cell lung cancer (NSCLC): Updated results from a phase I study |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Jianya Zhou; Xiaochen Zhang; Chengxiang Guo; Hui Wang; Yuping Sun; et al 出版日期:2026-06-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)